Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin-induced type 1 diabetes in rats.

Alomari, G; Al-Trad, B; Hamdan, S; Aljabali, AAA; Al Zoubi, MS; Al-Batanyeh, K; Qar, J; Eaton, GJ; Alkaraki, AK; Alshaer, W; Haifawi, S; Jemon, K; Chellappan, DK; Dua, K; Tambuwala, MM

Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin-induced type 1 diabetes in rats.

Alomari, G Al-Trad, B Hamdan, S Aljabali, AAA Al Zoubi, MS Al-Batanyeh, K Qar, J Eaton, GJ Alkaraki, AK Alshaer, W Haifawi, S Jemon, K Chellappan, DK Dua, K

Tambuwala, MM

Permalink

Publisher:: Institution of Engineering and Technology (IET)
Publication Type:: Journal Article
Citation:: IET nanobiotechnology, 2021, 15, (5), pp. 473-483
Issue Date:: 2021-07

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published versionAdobe PDF (1.58 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Alomari, G
dc.contributor.author	Al-Trad, B
dc.contributor.author	Hamdan, S
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Al Zoubi, MS
dc.contributor.author	Al-Batanyeh, K
dc.contributor.author	Qar, J
dc.contributor.author	Eaton, GJ
dc.contributor.author	Alkaraki, AK
dc.contributor.author	Alshaer, W
dc.contributor.author	Haifawi, S
dc.contributor.author	Jemon, K
dc.contributor.author	Chellappan, DK
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2021-12-28T00:39:40Z
dc.date.available	2020-11-06
dc.date.available	2021-12-28T00:39:40Z
dc.date.issued	2021-07
dc.identifier.citation	IET nanobiotechnology, 2021, 15, (5), pp. 473-483
dc.identifier.issn	1751-8741
dc.identifier.issn	1751-875X
dc.identifier.uri	http://hdl.handle.net/10453/152541
dc.description.abstract	This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic nephropathy, which is the primary cause of mortality for diabetic patients with end-stage renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7 weeks. Diabetes was associated with increases in blood glucose level, 24-h urinary albumin excretion rate, glomerular basement membrane thickness, renal oxidative stress markers, and renal mRNA or protein expression of transforming growth factor-β1, fibronectin, collagen-IV, tumour necrosis factor-α and vascular endothelial growth factor-A. Moreover, the expression of nephrin and podocin, and the mRNA expression of matrix metalloproteinase-9 were decreased in the diabetic group. These changes were not detected in the control group and were significantly prevented by ZnONP treatment. These results provide evidence that ZnONPs ameliorate the renal damage induced in a diabetic rat model of nephropathy through improving renal functionality; inhibiting renal fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the development of podocyte injury. The present findings may help design the clinical application of ZnONPs for protection against the development of diabetic nephropathy.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Institution of Engineering and Technology (IET)
dc.relation.ispartof	IET nanobiotechnology
dc.relation.isbasedon	10.1049/nbt2.12026
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	0906 Electrical and Electronic Engineering, 1003 Industrial Biotechnology
dc.subject.classification	Nanoscience & Nanotechnology
dc.subject.mesh	Kidney
dc.subject.mesh	Animals
dc.subject.mesh	Humans
dc.subject.mesh	Rats
dc.subject.mesh	Diabetic Nephropathies
dc.subject.mesh	Diabetes Mellitus, Experimental
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Zinc Oxide
dc.subject.mesh	Streptozocin
dc.subject.mesh	Vascular Endothelial Growth Factor A
dc.subject.mesh	Male
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Animals
dc.subject.mesh	Diabetes Mellitus, Experimental
dc.subject.mesh	Diabetes Mellitus, Type 1
dc.subject.mesh	Diabetic Nephropathies
dc.subject.mesh	Humans
dc.subject.mesh	Kidney
dc.subject.mesh	Male
dc.subject.mesh	Nanoparticles
dc.subject.mesh	Rats
dc.subject.mesh	Streptozocin
dc.subject.mesh	Vascular Endothelial Growth Factor A
dc.subject.mesh	Zinc Oxide
dc.title	Alleviation of diabetic nephropathy by zinc oxide nanoparticles in streptozotocin-induced type 1 diabetes in rats.
dc.type	Journal Article
utslib.citation.volume	15
utslib.location.activity	United States
utslib.for	0906 Electrical and Electronic Engineering
utslib.for	1003 Industrial Biotechnology
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/Graduate School of Health/GSH.Pharmacy
utslib.copyright.status	open_access	*
dc.date.updated	2021-12-28T00:39:38Z
pubs.issue	5
pubs.publication-status	Published
pubs.volume	15
utslib.citation.issue	5

Abstract:

This study examines the effect of nanoparticles with zinc oxides (ZnONPs) on diabetic nephropathy, which is the primary cause of mortality for diabetic patients with end-stage renal disease. Diabetes in adult male rats was induced via intraperitoneal injection of streptozotocin. ZnONPs were intraperitoneally administered to diabetic rats daily for 7 weeks. Diabetes was associated with increases in blood glucose level, 24-h urinary albumin excretion rate, glomerular basement membrane thickness, renal oxidative stress markers, and renal mRNA or protein expression of transforming growth factor-β1, fibronectin, collagen-IV, tumour necrosis factor-α and vascular endothelial growth factor-A. Moreover, the expression of nephrin and podocin, and the mRNA expression of matrix metalloproteinase-9 were decreased in the diabetic group. These changes were not detected in the control group and were significantly prevented by ZnONP treatment. These results provide evidence that ZnONPs ameliorate the renal damage induced in a diabetic rat model of nephropathy through improving renal functionality; inhibiting renal fibrosis, oxidative stress, inflammation and abnormal angiogenesis; and delaying the development of podocyte injury. The present findings may help design the clinical application of ZnONPs for protection against the development of diabetic nephropathy.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/152541